Clozapine protects bone mineral density in female patients with schizophrenia. 2012

Chieh-Hsin Lin, and Kuo-Hao Huang, and Yue-Cune Chang, and Yi-Chen Huang, and Wan-Chih Hsu, and Chun-Yuan Lin, and Frank Huang-Chih Chou, and Guochuan E Tsai, and Hsien-Yuan Lane
Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan.

Decreased bone mineral density (BMD) is common in patients with schizophrenia; however, the pathogenesis is unclear. Different classes of antipsychotic agents may affect BMD. This study systemically examined the effects of clozapine vs. other antipsychotics, and several hormonal and metabolic factors that may contribute to BMD in female patients with schizophrenia, who are more vulnerable than males. Forty-eight women with schizophrenia, treated with long-term antipsychotics of the prototype prolactin-sparing (PS) antipsychotic agent clozapine vs. prolactin-raising (PR) antipsychotics were enrolled. They were matched for demographic and clinical characteristics. Various factors, including blood levels of prolactin and sex hormones, psychopathological symptoms, global assessment of functioning, physical activity, and menopausal status, were determined to explore their contribution to low BMD (LBMD), defined as a dual-energy X-ray absorptiometer (DEXA) T score <-1. Overall, women receiving clozapine have better bone density than women receiving PR antipsychotics. Compared to PR antipsychotics, PS clozapine therapy is a protective factor (odds ratio 28.2, 95% confidence interval 2.37-336.10, p=0.008) for LBMD. Predictors for higher bone density in the clozapine group included higher clozapine dose (p<0.001), younger age (p<0.001), and higher thyroid-stimulating hormone level (p<0.001); in the PR group, higher body mass index (p=0.003) and lower alkaline phosphatase level (p=0.007) were associated with LBMD. This study suggests that clozapine treatment is beneficial for BMD compared to PR antipsychotic treatment in women with chronic schizophrenia, and clozapine's bone-density protecting effect is dose-related.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D003024 Clozapine A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. Clozaril,Leponex
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder
D013624 Taiwan Country in eastern Asia, islands bordering the East China Sea, Philippine Sea, South China Sea, and Taiwan Strait, north of the Philippines, off the southeastern coast of China. The capital is Taipei. The alternate country name is Republic of China. Formosa,Republic of China
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major
D015502 Absorptiometry, Photon A noninvasive method for assessing BODY COMPOSITION. It is based on the differential absorption of X-RAYS (or GAMMA RAYS) by different tissues such as bone, fat and other soft tissues. The source of (X-ray or gamma-ray) photon beam is generated either from radioisotopes such as GADOLINIUM 153, IODINE 125, or Americanium 241 which emit GAMMA RAYS in the appropriate range; or from an X-ray tube which produces X-RAYS in the desired range. It is primarily used for quantitating BONE MINERAL CONTENT, especially for the diagnosis of OSTEOPOROSIS, and also in measuring BONE MINERALIZATION. Absorptiometry, X-Ray,Dual-Photon Absorptiometry,Photodensitometry, X-Ray,Photon Absorptiometry,Single-Photon Absorptiometry,X-Ray Absorptiometry,Absorptiometry, Dual X-Ray,Absorptiometry, Dual-Energy Radiographic,Absorptiometry, Dual-Energy X-Ray,DEXA Scan,DPX Absorptiometry,DXA Scan,Densitometry, X-Ray,Densitometry, Xray,Dual X-Ray Absorptiometry,Dual-Energy Radiographic Absorptiometry,Dual-Energy X-Ray Absorptiometry,Dual-Energy X-Ray Absorptiometry Scan,Radiographic Absorptiometry, Dual-Energy,X-Ray Absorptiometry, Dual-Energy,X-Ray Photodensitometry,Absorptiometries, DPX,Absorptiometry, DPX,Absorptiometry, Dual Energy Radiographic,Absorptiometry, Dual Energy X Ray,Absorptiometry, Dual X Ray,Absorptiometry, Dual-Photon,Absorptiometry, Single-Photon,Absorptiometry, X Ray,DEXA Scans,DXA Scans,Densitometry, X Ray,Dual Energy Radiographic Absorptiometry,Dual Energy X Ray Absorptiometry,Dual Energy X Ray Absorptiometry Scan,Dual Photon Absorptiometry,Dual X Ray Absorptiometry,Photodensitometry, X Ray,Radiographic Absorptiometry, Dual Energy,Scan, DEXA,Scan, DXA,Scans, DEXA,Scans, DXA,Single Photon Absorptiometry,X Ray Absorptiometry,X Ray Absorptiometry, Dual Energy,X Ray Photodensitometry,X-Ray Absorptiometry, Dual,X-Ray Densitometry,Xray Densitometry

Related Publications

Chieh-Hsin Lin, and Kuo-Hao Huang, and Yue-Cune Chang, and Yi-Chen Huang, and Wan-Chih Hsu, and Chun-Yuan Lin, and Frank Huang-Chih Chou, and Guochuan E Tsai, and Hsien-Yuan Lane
September 2005, Schizophrenia research,
Chieh-Hsin Lin, and Kuo-Hao Huang, and Yue-Cune Chang, and Yi-Chen Huang, and Wan-Chih Hsu, and Chun-Yuan Lin, and Frank Huang-Chih Chou, and Guochuan E Tsai, and Hsien-Yuan Lane
July 2003, The Journal of clinical psychiatry,
Chieh-Hsin Lin, and Kuo-Hao Huang, and Yue-Cune Chang, and Yi-Chen Huang, and Wan-Chih Hsu, and Chun-Yuan Lin, and Frank Huang-Chih Chou, and Guochuan E Tsai, and Hsien-Yuan Lane
July 2005, Schizophrenia research,
Chieh-Hsin Lin, and Kuo-Hao Huang, and Yue-Cune Chang, and Yi-Chen Huang, and Wan-Chih Hsu, and Chun-Yuan Lin, and Frank Huang-Chih Chou, and Guochuan E Tsai, and Hsien-Yuan Lane
May 2008, Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences,
Chieh-Hsin Lin, and Kuo-Hao Huang, and Yue-Cune Chang, and Yi-Chen Huang, and Wan-Chih Hsu, and Chun-Yuan Lin, and Frank Huang-Chih Chou, and Guochuan E Tsai, and Hsien-Yuan Lane
January 2006, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists,
Chieh-Hsin Lin, and Kuo-Hao Huang, and Yue-Cune Chang, and Yi-Chen Huang, and Wan-Chih Hsu, and Chun-Yuan Lin, and Frank Huang-Chih Chou, and Guochuan E Tsai, and Hsien-Yuan Lane
August 2011, Journal of clinical psychopharmacology,
Chieh-Hsin Lin, and Kuo-Hao Huang, and Yue-Cune Chang, and Yi-Chen Huang, and Wan-Chih Hsu, and Chun-Yuan Lin, and Frank Huang-Chih Chou, and Guochuan E Tsai, and Hsien-Yuan Lane
January 2004, Schizophrenia research,
Chieh-Hsin Lin, and Kuo-Hao Huang, and Yue-Cune Chang, and Yi-Chen Huang, and Wan-Chih Hsu, and Chun-Yuan Lin, and Frank Huang-Chih Chou, and Guochuan E Tsai, and Hsien-Yuan Lane
January 2003, Schizophrenia research,
Chieh-Hsin Lin, and Kuo-Hao Huang, and Yue-Cune Chang, and Yi-Chen Huang, and Wan-Chih Hsu, and Chun-Yuan Lin, and Frank Huang-Chih Chou, and Guochuan E Tsai, and Hsien-Yuan Lane
November 1992, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics,
Chieh-Hsin Lin, and Kuo-Hao Huang, and Yue-Cune Chang, and Yi-Chen Huang, and Wan-Chih Hsu, and Chun-Yuan Lin, and Frank Huang-Chih Chou, and Guochuan E Tsai, and Hsien-Yuan Lane
March 2004, Saudi medical journal,
Copied contents to your clipboard!